CBU
LCTX icon

CIBC Bancorp USA’s Lineage Cell Therapeutics LCTX Stock Holding History

CIBC Bancorp USA’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.3K Buy
+10,174
New +$14.1K ﹤0.01% 1925

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

CIBC Bancorp USA's LCTX Position: Q2 2026 in Review

CIBC Bancorp USA opened a new position in Lineage Cell Therapeutics (LCTX) in Q2 2026: 10,174 shares worth $13.3K. The stake represents ﹤0.01% of the portfolio and ranks #1925 among its holdings.

126 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.

  • CIBC Bancorp USA held 10,174 shares of Lineage Cell Therapeutics worth $13.3K as of Q2 2026.
  • Lineage Cell Therapeutics was a new CIBC Bancorp USA position in Q2 2026.
  • Lineage Cell Therapeutics made up ﹤0.01% of CIBC Bancorp USA's portfolio in Q2 2026, its #1925 holding.
  • 126 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.

Based on CIBC Bancorp USA's 13F filing for Q2 2026, filed 13 Aug 2026.